BAN2401 (lecanemab) is an investigational medication designed to target and remove beta-amyloid proteins from the brain. It belongs to a class of drugs called monoclonal antibodies. This medication works by binding to and clearing out harmful amyloid protein deposits that are thought to contribute to the development of Alzheimer’s disease. It is administered through intravenous infusion and is being studied for its potential to slow down or prevent the progression of Alzheimer’s disease in people who have early signs or are at risk of developing the condition.

Preclinical Alzheimer’s Disease – A phase that occurs before the clinical symptoms of Alzheimer’s disease become apparent. During this stage, changes begin to occur in the brain, particularly the accumulation of amyloid protein, but individuals remain cognitively normal. This condition involves gradual biological changes that can start many years before noticeable memory problems develop. People in this stage maintain their ability to perform daily activities and may not show any obvious signs of cognitive decline.

Early Preclinical Alzheimer’s Disease – The earliest detectable stage of Alzheimer’s disease progression, characterized by subtle brain changes and intermediate levels of amyloid protein accumulation. During this phase, individuals maintain normal cognitive function and independence in daily activities. The brain undergoes early biological changes, though these changes are not yet severe enough to cause noticeable symptoms. This stage represents a crucial period where disease processes have begun but have not yet impacted cognitive abilities.